Promega launches new ADCC bioassay

By The Science Advisory Board staff writers

March 3, 2021 -- Promega has partnered with BioIVT to develop a new bioassay to measure the antibody-dependent cellular cytotoxicity (ADCC) of antibodies during drug development and characterization.

The new peripheral blood mononuclear cells (PBMC) ADCC Bioassay incorporates an add-mix-read format and sensitive luminescent readout, yielding a robust assay window. There are several assay formats available that provide ADCC-qualified PBMC effector cells and several target cells expressing a HiBiT (tiny NanoLuc binary technology) fusion protein that is detected using bioluminescence.

The assay functions by incubating HiBiT-expressing target cells with an antibody and a PBMC, which results in cellular lysing and the release of HiBiT proteins. These proteins bind to complementary large binary technology subunits (LgBiT) in the detection reagent to reconstitute functional NanoLuc binary technology (NanoBiT) luciferase and generate luminescence.

The cell-based assay was developed to mimic in vivo situations, according to Jey Cheng, a Promega senior research scientist in bioassay development.

Benchtop capillary electrophoresis opens new doors for sample identification
Sample identification and verification is essential to research that interrogates and compares specific regions of the human genome, called short tandem...
Promega launches benchtop CE DNA analyzer
Promega has debuted Spectrum Compact CE, a benchtop capillary electrophoresis (CE) instrument.
Shortage of RNA extraction kits threatens coronavirus testing
The weak link in the U.S. response to diagnostic testing for the novel coronavirus SARS-CoV-2 could be a shortage of RNA extraction kits. Fortunately,...
MilliporeSigma licenses CRISPR tech to Promega
MilliporeSigma announced on December 19 that it has signed a license agreement providing Promega Corp., access to MilliporeSigma's foundational CRISPR...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter